Maxime Dely: Trends in Red Blood Cell Consumption in France
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Trends in Red Blood Cell (RBC) consumption in France
- A steady decline over the past decade
Over the last ten years, a clear trend has emerged: overall RBC consumption in France has been steadily decreasing.
This evolution is largely driven by major advances in medical and surgical practices. Procedures are now more targeted and minimally invasive, with better anticipation of bleeding risks.
At the same time, transfusion best practices have evolved significantly: the goal is no longer to transfuse more, but to transfuse appropriately, avoiding unnecessary over-transfusion.
- Fewer standard RBC units, but more relevant transfusion strategies.
- A significant shift in the nature of transfusion needs
This overall decline does not mean that transfusion challenges are disappearing. On the contrary, the profile of needs is changing.
In France, a genetic disease remains highly prevalent: sickle cell disease.
These patients often require regular red blood cell exchange transfusions, frequently performed through erythrocytapheresis, and depend on RBC units with rare blood group phenotypes.
- A dual dynamic to consider
We are now facing a clear correlation: a decrease in standard RBC consumption, alongside an increase in demand for highly specific and rare RBC units.
- A direct impact on donor recruitment strategies
This shift is profoundly reshaping donor recruitment and communication strategies.
Where “standard” donor profiles were largely sufficient 10–15 years ago, there is now a growing need for targeted outreach, focused on donors with rare blood groups.
- Transfusion medicine is evolving.
- Blood donor recruitment must evolve with it.”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026
-
May 6, 2026, 02:38Moustafa Abdou: Is the Bone Marrow Examination Still the ‘Gold Standard’?
-
May 6, 2026, 02:23Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
-
May 6, 2026, 02:12Caitlin Raymond: How STOP-BABESIOSIS Just Rewrote 40 Years of Practice
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention